Navigation Links
Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
Date:9/24/2008

SAN MATEO, Calif., Sept. 24 /PRNewswire/ -- Anthera Pharmaceuticals announced today they have reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase 3 protocol for varespladib (A-002) in acute coronary syndrome (ACS) under the FDA's Special Protocol Assessment procedure. At the same time, the company received Scientific Advice from the European Medicines Agency (EMEA) on Anthera's European development strategy for varespladib. Guidance from both regulatory agencies regarding varespladib will be incorporated into Anthera's global registration program slated to start next year.

Anthera's Special Protocol Assessment supports a single, pivotal, Phase 3 trial evaluating varespladib, in combination with Lipitor(R) (atorvastatin) as first-line treatment within 96 hours of an ACS event. In the European Union, Anthera received Scientific Advice that supports a similar clinical development program and include the potential to also utilize varespladib as an adjunctive treatment in patients with stable coronary disease and elevated levels of LDL-C and total cholesterol.

"We are pleased that both agencies recognized the potential of varespladib's multiple therapeutic effects in patients with cardiovascular disease," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The anti-inflammatory effect and safety profile seen in the varespladib trials to date are very exciting and highlight the opportunity to help patients with recent coronary events."

"The regulatory clarity in the United States and Europe reinforces our confidence that we can efficiently deliver a novel therapeutic for patients with ACS," said Dr. Ursula Fritsch, Vice-President Global Regulatory and Compliance. "With this regulatory feedback, we have a clearly defined and reasonable development path to deliver a first in class therapeutic for ACS patients and individuals with hypercholesterolemia."

"The recent publication o
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
7. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
8. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
9. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
10. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Transparency Market ... Acid (MCA) Market for Cellulosics, Agrochemicals, Surfactants, Thioglycolic Acid ... Share, Growth, Trends and Forecast 2014 - 2020". The ... million in 2013 and is anticipated to reach USD ... 3.6% during the forecast period from 2014 to 2020. ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: Global Coatings ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report analyzes ... in US$ Million by the following Product Segments: ... Coatings. The report provides separate comprehensive analytics for ...
(Date:8/20/2014)... 2014 Reportlinker.com announces that a new market ... Global Feminine Hygiene Products Industry ... markets for Feminine Hygiene Products in US$ Million by ... and Others. The report provides separate comprehensive analytics for ... Japan , Europe , ...
Breaking Medicine Technology:Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13
... In an effort to meet industry demands ... safe and accurate administration, B. Braun Medical Inc. ... Cefepime for Injection USP and Dextrose Injection USP ... Delivery System will be available for purchase ...
... Johnson & Johnson (NYSE: JNJ ) will ... on Tuesday, Oct. 19, 2010, to discuss third-quarter financial ... be hosted by Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group; ... and Louise Mehrotra, Vice President, Investor Relations. ...
Cached Medicine Technology:FDA-Approved Cefepime Now Available for Use in B. Braun's DUPLEX® System 2
(Date:8/20/2014)... Aug. 19, 2014 (HealthDay News) -- A group representing ... get a flu shot. According to the American ... in recent years have upheld the safety and effectiveness ... is highly infectious and can be particularly dangerous to ... and other complications," Dr. Laura Riley, chair of the ...
(Date:8/20/2014)... that the immune system is defective in people suffering from ... have ongoing issues with pain. , The research the ... help to explain why some painkillers may not offer satisfactory ... to 10% of the community. There are different forms ... which often has the greatest impact on sufferers, quality of ...
(Date:8/20/2014)... Barbara Bronson Gray HealthDay Reporter ... extremely rare, colds, flu and other minor infections might ... stroke in children, a new study suggests. Just five ... the United States, said Dr. Heather Fullerton, lead author of ... the University of California, San Francisco Benioff Children,s Hospital. "It ...
(Date:8/20/2014)... 2014 The Board of Directors of ... is pleased to announce the expansion of its ... China and the surrounding region. In support of ... AIA has relocated to the firm’s office in ... planning and design and to better support regional clients. ...
(Date:8/20/2014)... City, Utah (PRWEB) August 20, 2014 With ... 500’s 2014 list of the nation’s fastest growing companies. The ... in the health care sector. Connexion Point is the #1 ... contact centers in Medicare and Medicaid, and its clients include ... nation. Connexion Point employs 1,000 people and has offices and ...
Breaking Medicine News(10 mins):Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... Wash., April 16 drugstore.com , inc. (Nasdaq: ... vision, and pharmacy products, will announce its financial results for ... April 29, 2009 at 5:00 p.m. ET (2:00 p.m. PT). ... will be distributed via PR Newswire and posted on the ...
... workshops to exchange ideas with experts on clinical ... PRA International, a leading Clinical ... how to manage the challenges posed by current ... marketing approvals, and increase efficiency working with different ...
... and effect , , THURSDAY, April 16 (HealthDay News) -- ... and C in their diet may be at increased risk ... 40 studies conducted between 1980 and 2007 showed that people ... A than those without the disease. The average intake among ...
... Patients and Their Loved OnesMOUNT SHASTA, Calif., April 16 ... sweeter, more mystifying sound than the elusive words SPONTANEOUS REMISSION," ... The semi-Buddhist answer to dancing with Cancer ... YOU LEAD" ... this miraculous phenomenon was not a spontaneous event at all ...
... Abbott/Eisai,s Humira Will Earn Decision Resources, Clinical Gold ... to a New Report from Decision ResourcesWALTHAM, Mass., ... world,s leading research and advisory firms for pharmaceutical ... a therapy,s effect on induction of remission as ...
... Chance to Look Like a Star with Milk on ... Only at bodybymilk.comWASHINGTON , April 16 Warding ... superheroes like Wolverine need a little help. (Photo: ... to rebuild his body far faster than any ordinary ...
Cached Medicine News:Health News:drugstore.com, inc. to Announce First Quarter 2009 Results During Conference Call on Wednesday, April 29, 2009 at 5:00 p.m. ET 2Health News:PRA Hosts Biotech 2009 - Challenges and Opportunities in R&D 2Health News:Low Vitamin E, C Intake Tied to Asthma Risk 2Health News:New Guidebook Uses Buddhist Principles to Combat Cancer 2Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 2Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 3Health News:X-Men's Wolverine Depends on Milk as His X-factor 2
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Standard Erlanger hip stem....
Cemented foundation 460 series....
Medicine Products: